Page 44 - Mployee Wellness Programs News Today

By understanding the interconnectedness of the healthcare industry, aligning goals and maintaining an open line of communication, distributors and healthcare organizations can cultivate lasting, dependable partnerships, while working together to develop innovative ideas and solutions.

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Too often, executives look to data retrospectively to understand what has happened, rather than using data prescriptively to understand what is likely to happen and, in turn, how to best respond.

Many new to financing negotiations try to paint a rosy picture and offer unrealistic terms or revenue expectations to improve a soured relationship. This will quickly backfire and result in defaults, which not only incurs additional costs, but can rupture trust and spoil relationships.

UI affects 78 million women in the U.S. while fecal incontinence affects 12 million. Prevalence is rising. Age and obesity are associated with increased risk of UI, and both contribute to its increased incidence. Globally, hundreds of millions of women are affected.

Canopy has emerged from stealth as a startup focused on protecting healthcare staff from increasing levels of violence. The company’s product, called Canopy Protect, involves wearable monitors that healthcare staff can press when they feel threatened, as well as a system that allows a hospital to monitor all physical areas of the organization.

Recognizing and responding to this new emphasis on patient engagement isn’t easy. It requires providers to abandon a long-held model of healthcare with clinicians squarely at the center in favor of one in which the patients are in charge – and easily lost – if their wishes are not met.

Our current system is broken. It only allows for the evaluation of symptoms and the treatment of disease. We need to adapt to the reality of an aging population and encourage everyone to age well.

FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.

Ketryx raised $14 million in Series A funds. The startups sells a platform — designed around FDA regulations and quality standards — that automates much of the work required from medical device companies’ development and quality teams.